KRAS mutations have been identified in early stage endometrial hyperplasia specimens [56] and due to their biological function to support tumor proliferation, by assessing the presence of this mutation may offer an opportunity to predict tumor invasiveness [57]. The gene discussed is KRAS; the disease is neoplasm.